Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Blood

Volumn 126, Issue 15, 2015, Pages 1762-1769

  Gisslinger, Heinz ^a   Zagrijtschuk, Oleh ^b   Buxhofer Ausch, Veronika ^c,d   Thaler, Josef ^e   Schloegl, Ernst ^f   Gastl, Guenther A ^g   Wolf, Dominik ^g,h   Kralovics, Robert ^a,i   Gisslinger, Bettina ^a   Strecker, Karin ^c   Egle, Alexander ^j   Melchardt, Thomas ^j   Burgstaller, Sonja ^e   Willenbacher, Ella ^g   Schalling, Martin ^a   Them, Nicole C ⁱ   Kadlecova, Pavla ^k   Klade, Christoph ^b   Greil, Richard ^j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AOP Orphan Pharmaceuticals AG   (Austria)

^c DANUBE HOSPITAL   (Austria)

^d ELISABETHINEN HOSPITAL   (Austria)

^e Hospital Wels Grieskirchen   (Austria)

^f HANUSCH HOSPITAL   (Austria)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^j PARACELSUS MEDICAL UNIVERSITY   (Austria)

^k Advanced Drug and Device Services SAS   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ROPEGINTERFERON ALPHA2B; ALPHA INTERFERON; ALPHA2B INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE STRESS DISORDER; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE THYROIDITIS; CHILL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; ELIMINATION HALF-LIFE; FATIGUE; FEMALE; FEVER; HALLUCINATION; HEADACHE; HUMAN; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LISTLESSNESS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERTIGO; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL; FOLLOW UP; HALF LIFE TIME; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; INTERFERON-ALPHA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; POLYCYTHEMIA VERA; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84943624287     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-637280     Document Type: Article

References (26)

1. Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses]. Acta Med Austriaca. 1985;12(5):123-127.
2. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989;1(8639):634-637.
3. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferonalpha. Cancer. 2006;107(3):451-458.
4. Heis N, Rintelen C, Gisslinger B, Knöbl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 1999;62(1):27-31.
5. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
6. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
7. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
9. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-2040.
10. Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Prog. 2012;561-566.
11. Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABLnegative myeloproliferative neoplasms. J Interferon Cytokine Res. 2013;33(4):145-153.
12. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-5424.
13. Hasselbalch HC. A new era for IFN-a in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637-655.
14. Talpaz M, O'Brien S, Rose E, et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001;98(6):1708-1713.
15. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51(1):81-86.
16. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90(10):1333-1338.
17. Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branched-chain longacting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res. 2005;11(17): 6247-6255.
18. Samuelsson J, Hasselbalch H, Bruserud O, et al; Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106(11):2397-2405.
19. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110(9):2012-2018.
20. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8): 3065-3072.
21. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013; 122(6):893-901.
22. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18): 4706-4715.
23. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49-58.
24. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, et al. Thyroid autoimmunity and hypothyroidism during longterm treatment with recombinant interferon-alpha. Clin Exp Immunol. 1992;90(3):363-367.
25. Crowley JC, Ankerst DP, eds. Handbook of statistics in clinical oncology. 2nd ed. Boca Raton: Chapman & Hall/CRC Taylor & Francis Group; 2006.
26. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-4833.